Aytu BioPharma (NASDAQ:AYTU) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

Aytu BioPharma, Inc. (NASDAQ:AYTU) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.59 and traded as low as $1.34. Aytu BioPharma shares last traded at $1.35, with a volume of 64,208 shares traded.

Aytu BioPharma Stock Performance

The firm has a market capitalization of $8.33 million, a price-to-earnings ratio of -0.93 and a beta of -1.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.98 and a quick ratio of 0.81. The firm has a 50 day moving average price of $1.59 and a 200-day moving average price of $1.95.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.28) earnings per share (EPS) for the quarter. Aytu BioPharma had a negative net margin of 7.62% and a negative return on equity of 19.30%.

Institutional Trading of Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC increased its stake in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 500,958 shares of the company’s stock after acquiring an additional 28,489 shares during the period. Aytu BioPharma makes up about 0.7% of Stonepine Capital Management LLC’s holdings, making the stock its 25th largest holding. Stonepine Capital Management LLC owned about 8.15% of Aytu BioPharma worth $1,177,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.